

May 29, 2019

The Corporate Relationship Dept. BSE Limited 1st Floor, P.J.Towers Rotunda Building Dalal Street, Fort Mumbai - 400 001 The Manager Listing Dept. The National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor, Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051

Dear Sir,

Ref: BSE Scrip Code -506690: NSE Symbol - UNICHEMLAB

<u>Sub.: Compliance Under Regulation 47 of the SEBI (Listing Obligations And</u> Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Dear Sir/Madam,

Pursuant to Regulation 47 of the Listing Regulations, please find enclosed copy of financial results of the Company for the quarter and year ended March 31, 2019 published in the following newspapers on May 25, 2019.

1. Mumbai edition of Business Standard

2. Mumbai edition of Sakal

Kindly take the same on your records.

Thanking you, FOR UNICHEM LABORATORIES LIMITED

C.A. Maken

Neema Thakore Head- Legal & Company Secretary Encl: a/a

Veekend Business Standard MUMBAI | 25 MAY 2019



CIN:L99999MH1962PLC012451

Regid. Office: Unichem Bhavan, Prabhat Estate, of S.V. Road, Jogeshwari (West), Mumbai - 400 102 .Tel. No.: 91 (22) 6688 8333 • Fax. No.: 91 (22) 2678 4391

Website: www.unichemlabs.com • E-mail ID.: shares8unichemlabs.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2019.

Γ.			-	Standalone		1.6 1.4	Conso	idated
	Particulars	Quarter ended 31st Mar'19 (Unaudited)	Quarter ended 31st Dec'18 (Unaudited)	Quarter ended 31st Mar'18 (Audited)	Year ended 31st Mar'19 (Audited)	Year ended 31st Mar' 18 (Audited)	Year ended 31st Mar'19 (Audited)	Year ended 31st Mar' 18 (Audited)
1	Total income (excluding other income) from continuing operations	27,708.14	24,436.12	20,344.28	96,773.89	66,646.97	118,004.68	81,498.48
2	Profit / (loss) before tax from continuing operations	(38.24)	(901.90)	617.55	(2,158.02)	(12,155.04)	(5,990.53)	(12,975.55)
3	Profit / (loss) before tax from discontinued operations (Refer note 2)	974.25	(367.94)	229.13	246.96	337,089.17	246.96	337,089.17
4	Profit / (loss) for the period from continuing operations after tax	369.28	632.05	280.45	704.20	(12,140.95)	(2,555.76)	(13,309.77)
5	Profit / (loss) for the period from discontinued operations after tax	625.01	(201.94)	(55.70)	175.72	267,800.80	175.72	267,800.80
e	Total Comprehensive Income for the period [Comprising of Profit/(Loss) for the period (after tax) and	9. 1911	ж. Т				(0.400.07)	
ŀ	other comprehensive income (after tax)]	972.52	357.78			255,479.77	and the second s	254,032.40
17	Paid-up Equity Share Capital	1,407.67	1,407.67	1,406.74				1,406.74
8	Other Equity [Reserves excluding Revaluation Reserve]			1	271,785.74	274,759.86	260,583.02	266,601.64
0	P Earnings per share (of ₹ 2/- each) from continuing operations and discontinuedoperations (in ₹)							
	(a) Basic	1.41	0.61	0.25	1.25	281.88	(3.38)	280.60
	(b) Diluted	1.41	0.61	0.25	1.25	281.70	(3.38)	280.41

Notes:

The standalone financial results for the quarter and year ended 31st March, 2019 and consolidated financial results for the year ended 31st 1 March 2019 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 24th May, 2019. The statutory auditors have expressed an unqualified audit opinion on these standalone and consolidated financial results. The above is an extract of the detailed format of the standalone and consolidated financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of these standalone and consolidated financial results are available on the websites of the Stock Exchanges i.e. www.bseindia.com and www.nseindia.com and the Company at www.unichemlabs.com.

2 During the year ended 31st March 2018, based on the approval obtained from the Shareholders, the Company had transferred its business of manufacture, sale, marketing and distribution of domestic formulations in India and Nepal ("Identified Business") by way of slump sale on going concern basis to Torrent Pharmaceuticals Limited ("Torrent"). Identified business includes portfolio of several brands in India and Nepal, manufacturing facility at Sikkim and employees performing work in relation to said business. Gain on sale of Identified Business (net) amounting to ₹ 321,731.05 lakhs had been recognised and disclosed under discontinued operations in the above results.

The Board recommends a final dividend of ₹ 41- per share (200 %) (face value of ₹ 2/- per share) for the year ended 31st March, 2019. The 3 payment is subject to the approval of the shareholders in the ensuing Annual General Meeting of the Company.

By Order of the Board For Unichem Laboratories Limited Sd/-

Dr. Prakash A. Mody

Place: Mumbai Date: 24th May, 2019 Chairman & Managing Director DIN: 00001285





	ORAT	ORIES	LTD.	at a		r.	
-		1962PLC0					
Regd. Office: Unichem Bhavan, Prabl Tel. No.: 91 (22) 66			· •		lumbai • 40	0 102	
Website: www.unichemlab			• • •		com		
EXTRACT OF UNAUDITED FINANCIAL RESULTS ENI	网络瑞典斯马尔德 建合成可能 上口	QUARTER MARCH, 2) FINANCIA	AL RESULT	S FOR THE	EYEAR ₹ Lak
	<u></u>	Consolidated					
Particulars	Quarter	Quarter	Standalone Quarter	Year	Year	Year Year	
	ended 31st Mar'19 (Unaudited)	ended 31st Dec'18		ended	ended	ended 31st Mar'19 (Audited)	ended 31st Mar' (Audite
1 Total income (excluding other income) from continuing operations	27,708.14	24,436.12	20,344.28	96,773.89	66,646.97	118,004.68	81,498.4
2 Profit / (loss) before tax from continuing operations	(38.24)	(901.90)	617.55	Contraction of the second second	(12,155.04)	Sector of the sector sector sector sector	
3 Profit / (loss) before tax from discontinued operations (Refer note 2)	974.25	(367.94)	229.13	246.96	337,089.17	246.96	337,089.
4 Profit / (loss) for the period from continuing operations after tax ,	369.28	632.05	280.45	704.20	(12,140.95)	(2,555.76)	(13,309.7
5 Profit / (loss) for the period from discontinued operations after tax	625.01	(201.94)	(55.70)	175.72	267,800.80	175.72	267,800.
6 Total Comprehensive Income for the period [Comprising of Profit/(Loss) for the period (after tax) and							
other comprehensive income (after tax)]	972.52	357.78	10	100 00 0000	255,479.77		
7 Paid-up Equity Share Capital 8 Other Equity [Reserves excluding Revaluation Reserve]	1,407.67	1,407.67	1,406.74	1,407.67 271 785 74	1,406.74 274,759.86	1.00	1,406. 266,601.
 9 Eamings per share (of ₹ 2/- each) from continuing operations and discontinued operations (in ₹) 			e	211,700.74	21-1,100.00	200,000.02	200,001.
(a) Basic	1.41	0.61		1.25			280.
(b) Diluted	1.41	0.61	0.25	1.25	281.70	(3.38)	280.
 The standalone financial results for the quarter and year March 2019 have been reviewed by the Audit Commit 24th May, 2019. The statutory auditors have expressed The above is an extract of the detailed format of the s Regulation 33 of the SEBI (Listing Obligations and Dis consolidated financial results are available on the webs Company at www.unichemlabs.com. During the year ended 31st March 2018, based on the of manufacture, sale, marketing and distribution of do on going concern basis to Torrent PharmaceuticalsLin Nepal, manufacturingfacility at Sikkim and employees 	tee and app dan unquali standalone sclosure Re sites of the approval of mestic form nited ("Torre performing"	proved by the fied audit op and consoli quirements) Stock Exchat otained from ulations in li ulations in li ent"). Identifi work in relat	e Board of I inion on the dated finance Regulations nges i.e. ww the Shareho ndia and Ne ed business ion to said b	Directors of se standalor ial results fil s', 2015. The w.bseindia. dders, the C pal ("Identifi includes po usiness. Gai	the Compare he and consider with the a full formatic com and we company have de Busines ortfolio of set in on sale of	ny at its mee olidated fina Stock Excha of these sta ww.ns&india d transferred s") by way o veral brands I dentified Bi	ting held ncial resu anges un ndalone a com and lits busin f slump s in India a
amounting to ₹ 321,731.05 lakhs had been recognised 3 The Board recommends a final dividend of ₹ 4/- per sh payment is subject to the approval of the shareholder:	are (200 %)	(face value	of ₹ 2/- per	share) for th	ie year ende		h, 2019. T
			. 20.1010110	0		By Order	r of the Bories Lim
						Dr. Pral	ash A. M

,

.,